ICH Guidelines for Safety issues in Pharmaceutical Industry

S1A: Need for Carcinogenicity Studies of Pharmaceuticals

S1B: Testing for Carcinogenicity of Pharmaceuticals

S1C(R2): Dose Selection for Carcinogenicity Studies of Pharmaceuticals.

S2(R1): Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
S3A: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies

S3B: Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies.

S4: Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing).

S5(R2): Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility.

S6(R1): Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.

S7A: Safety Pharmacology Studies for Human Pharmaceuticals.

S7B: The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals.

S8: Immunotoxicity Studies for Human Pharmaceuticals.

S9: Nonclinical Evaluation for Anticancer Pharmaceuticals.

S10: Photosafety Evaluation of Pharmaceuticals.

International Conference of Harmonization for Quality